ofloxacin has been researched along with Tuberculosis, Pulmonary in 116 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Tuberculosis, Pulmonary: MYCOBACTERIUM infections of the lung.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to evaluate tuberculosis treatment including levofloxacin (LVFX) and to investigate the effectiveness of changing drug regimens at our hospital." | 7.77 | [Evaluation of tuberculosis treatment including levofloxacin (LVFX) in cases who could not continue standard regimen]. ( Akagawa, S; Ariga, H; Kaneko, Y; Kawabe, Y; Kawashima, M; Kunogi, M; Machida, K; Masuda, K; Matsui, H; Matsui, Y; Nagai, H; Nagayama, N; Nakajima, Y; Ohshima, N; Shimada, M; Suzuki, J; Tamura, A; Toyota, E, 2011) |
| "The ofloxacin (OFLX) concentration in serum, saliva and pleural effusion was measured in 12 patients with pleural effusion after oral administration at a dose of 200 mg three times a day (600 mg daily)." | 7.69 | Ofloxacin concentrations in serum, saliva and pleural effusion of patients with pulmonary tuberculosis and lung cancer. ( Goya, T; Hamakubo, S; Hanaoka, T; Hosaka, K; Miya, T, 1995) |
| "The purpose of this study was to evaluate tuberculosis treatment including levofloxacin (LVFX) and to investigate the effectiveness of changing drug regimens at our hospital." | 3.77 | [Evaluation of tuberculosis treatment including levofloxacin (LVFX) in cases who could not continue standard regimen]. ( Akagawa, S; Ariga, H; Kaneko, Y; Kawabe, Y; Kawashima, M; Kunogi, M; Machida, K; Masuda, K; Matsui, H; Matsui, Y; Nagai, H; Nagayama, N; Nakajima, Y; Ohshima, N; Shimada, M; Suzuki, J; Tamura, A; Toyota, E, 2011) |
| "The ofloxacin (OFLX) concentration in serum, saliva and pleural effusion was measured in 12 patients with pleural effusion after oral administration at a dose of 200 mg three times a day (600 mg daily)." | 3.69 | Ofloxacin concentrations in serum, saliva and pleural effusion of patients with pulmonary tuberculosis and lung cancer. ( Goya, T; Hamakubo, S; Hanaoka, T; Hosaka, K; Miya, T, 1995) |
| "The objective of this study was to determine the population pharmacokinetic parameters of levofloxacin, gatifloxacin, and moxifloxacin following multiple oral doses." | 2.73 | Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. ( Boom, WH; Dietze, R; Hadad, DJ; Johnson, JL; Molino, LP; Palaci, M; Peloquin, CA, 2008) |
| "After the completion of the treatment course, the negative sputum conversion rate in V+D+M treatment protocol group was 84%, significantly higher than that in the control group (42%); the former group showed a focal absorption rate and pulmonary cavity closure rate of 83% and 66%, which were 33% and 26% respectively in the latter." | 2.71 | [Short-term effect of treatment protocol utilizing levofloxacin, pasiniazide and M. Vaccae on multi- drug resistant pulmonary tuberculosis]. ( Li, SM; Xing, BC; Zheng, XM, 2004) |
| "Ofloxacin has antitubercular activity and has exclusive renal clearance." | 2.70 | Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report. ( Agarwal, SR; Nandeesh, HP; Saigal, S; Sarin, SK, 2001) |
| "Ofloxacin was given to 118 patients orally at a daily dose of 300 mg to 600 mg for more than 3 months." | 2.67 | [Therapeutic effect of ofloxacin on intractable pulmonary tuberculosis and ofloxacin resistance of tubercle bacilli isolated from the patients. Chest DIsease Cooperative Study Unit of National Sanatoriums in Kinki District]. ( Ikeda, N; Inoue, S; Kita, N; Matsumoto, T; Nakae, I; Nakatani, K; Ozawa, S; Sakatani, M; Takahasi, K; Tanaka, S, 1991) |
| "Two cases of chronic, cavernous pulmonary tuberculosis with bacilli resistant to several drugs are presented." | 2.66 | [2 cases of drug-resistant pulmonary tuberculosis treated with ofloxacin]. ( Krakówka, P; Krasucka-Kluźniak, A, 1989) |
| " We aim to compare the culture conversion between new-generation (levofloxacin and moxifloxacin) and old-generation (ciprofloxacin and ofloxacin) fluoroquinolones, develop pharmacokinetic models, and calculate target attainment for levofloxacin and moxifloxacin." | 1.51 | Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection. ( Ahmed, S; Al-Shaer, MH; Alghamdi, WA; Alkabab, Y; Alsultan, A; An, G; Banu, S; Barbakadze, K; Cegielski, JP; Heysell, SK; Houpt, E; Kempker, RR; Kipiani, M; Mikiashvili, L; Peloquin, CA, 2019) |
| "Antofloxacin (AFX) is a novel fluoroquinolone that has been approved in China for the treatment of infections caused by a variety of bacterial species." | 1.43 | Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin. ( Chen, S; Dong, L; Huang, H; Köser, CU; Moradigaravand, D; Parkhill, J; Peacock, SJ; Schön, T; Shang, Y; Wang, G; Wei, G; Yu, X, 2016) |
| " Lead optimization resulted in the identification of potent compounds with improved oral bioavailability and reduced cardiac ion channel liability." | 1.40 | Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis. ( Achar, V; Arora, U; Awasthy, D; Bharath, S; Bheemarao, U; Chinnapattu, M; Coulson, M; de Sousa, SM; Ganguly, S; Gaonkar, S; Ghosh, A; Hameed P, S; Hoffner, S; Humnabadkar, V; Kaur, P; Kumar K N, M; Kumar, CN; Madhavapeddi, P; Manjrekar, P; Menasinakai, S; Mukherjee, K; Nandishaiah, R; Narayan, C; Panduga, V; Patil, V; Puttur, J; Raichurkar, A; Ramya, VK; Reddy, J; Rudrapatana, S; Sambandamurthy, VK; Shanbhag, G; Sharma, S; Sharma, U; Shinde, V; Solapure, S; Waterson, D; Werngren, J, 2014) |
| "To investigate the effects of inactivation of CD(4)(+)CD(25)(+) regulatory T cells (Treg) combined with the administration of levofloxacin (LFX) on the cellular immune response of murine tuberculosis." | 1.35 | [The effect of CD4+ CD25+ regulatory T cell inactivation combined with levofloxacin on murine tuberculosis]. ( Chen, XC; Gou, JZ; Li, MZ; Peng, YZ; Tang, ZJ; Tong, XD; Yue, XH; Zhou, BP, 2009) |
| "The case experienced pyothorax due to pulmonary tuberculosis three years before and Mycobacterium avium pleuritis one year before this episode." | 1.35 | [Case of pneumothorax associated with pulmonary Mycobacterium fortuitum infection]. ( Baba, T; Endo, T; Hagiwara, E; Komatsu, S; Matsumoto, Y; Nishihira, R; Ogura, T; Sato, T; Sekine, A; Shinohara, T; Sogo, Y; Takahashi, H, 2008) |
| "47 patients with pulmonary tuberculosis received regimens including FQs were observed consecutively." | 1.32 | [A preliminary study on the definition of resistant breakpoints of ofloxacin and levofloxacin for Mycobacterium tuberculosis]. ( Gao, WW; Huang, XR; Ma, Y; Pan, YX; Wang, SM; Zhang, XX, 2004) |
| "We report a chronic case of pulmonary tuberculosis in a Malagasy citizen from Antsohihy (West of Madagascar), who was infected with a multi-drug resistant Mycobacterium bovis strain." | 1.32 | [A case of pulmonary multiresistant Mycobacterium bovis tuberculosis in Madagascar]. ( Andrianasolo, D; Ramarokoto, H; Ramaroson, F; Rasolofo Razanamparany, V; Rasolonavalona, T; Ratsimba, L; Razafitsiarovana, I; Vincent, V, 2003) |
| "We report a case of Mycobacterium abscessus infection complicated with diabetes mellitus." | 1.31 | [Mycobacterium abscessus infection complicated with diabetes mellitus]. ( Harada, H; Iwasaki, Y; Minagawa, T; Nagata, K; Nakagawa, M; Nakanishi, M; Natsuhara, A; Takemura, Y, 2002) |
| "Ofloxacin PK parameters were comparable to those previously published for other patient populations." | 1.31 | Ofloxacin population pharmacokinetics in patients with tuberculosis. ( Ashkin, D; Berning, SE; Bulpitt, AE; Hollender, ES; Narita, M; Peloquin, CA; Stambaugh, JJ, 2002) |
| "Treatment with ofloxacin in a combined regimen achieved a success rate of 78%." | 1.30 | Quinolones and multidrug-resistant tuberculosis. ( Maranetra, KN, 1999) |
| "Ciprofloxacin was used primarily to treat Mycobacterium avium complex (MAC) infection, dosed to achieve 2-hour post-dose serum concentrations of 4-6 micrograms/ml." | 1.29 | Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. ( Berning, SE; Iseman, MD; Madsen, L; Peloquin, CA, 1995) |
| "Sparfloxacin at 100 mg/kg was more active than LEV at 200 mg/kg; however, the activities of sparfloxacin at 50 mg/kg and LEV at 200 mg/kg were comparable." | 1.29 | Activity of levofloxacin in a murine model of tuberculosis. ( Cynamon, MH; Klemens, SP; Rogge, MC; Sharpe, CA, 1994) |
| "The properties of ofloxacin such as a new mechanism of action, broad spectrum and high antimicrobial activity, 100-percent bioavailability and rapid penetration to the body tissues, etc." | 1.29 | [Use of ofloxacin in infections which do not readily respond to treatment]. ( Zalaudek, G, 1996) |
| "Twenty-nine patients with extensive pulmonary tuberculosis and drug-induced hepatitis were treated with ofloxacin along with other relatively non-hepatotoxic drugs, either during the interim phase to await recovery of liver function in some, or as definitive therapy as required by the compromised hepatic status of others." | 1.28 | Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction. ( Kwan, SY; Lee, J; Wong, PC; Yew, WW, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (9.48) | 18.7374 |
| 1990's | 36 (31.03) | 18.2507 |
| 2000's | 40 (34.48) | 29.6817 |
| 2010's | 29 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hameed P, S | 1 |
| Patil, V | 1 |
| Solapure, S | 1 |
| Sharma, U | 1 |
| Madhavapeddi, P | 1 |
| Raichurkar, A | 1 |
| Chinnapattu, M | 1 |
| Manjrekar, P | 1 |
| Shanbhag, G | 1 |
| Puttur, J | 1 |
| Shinde, V | 1 |
| Menasinakai, S | 1 |
| Rudrapatana, S | 1 |
| Achar, V | 1 |
| Awasthy, D | 1 |
| Nandishaiah, R | 1 |
| Humnabadkar, V | 1 |
| Ghosh, A | 1 |
| Narayan, C | 1 |
| Ramya, VK | 1 |
| Kaur, P | 1 |
| Sharma, S | 1 |
| Werngren, J | 2 |
| Hoffner, S | 2 |
| Panduga, V | 1 |
| Kumar, CN | 1 |
| Reddy, J | 1 |
| Kumar K N, M | 1 |
| Ganguly, S | 1 |
| Bharath, S | 1 |
| Bheemarao, U | 1 |
| Mukherjee, K | 1 |
| Arora, U | 1 |
| Gaonkar, S | 1 |
| Coulson, M | 1 |
| Waterson, D | 1 |
| Sambandamurthy, VK | 1 |
| de Sousa, SM | 1 |
| Bablishvili, N | 2 |
| Tukvadze, N | 2 |
| Shashkina, E | 1 |
| Mathema, B | 1 |
| Gandhi, NR | 1 |
| Blumberg, HM | 2 |
| Kempker, RR | 3 |
| Calleris, G | 1 |
| Marra, G | 1 |
| Corcione, S | 1 |
| Oderda, M | 1 |
| Cardellino, C | 1 |
| Audagnotto, S | 1 |
| Frea, B | 1 |
| De Rosa, FG | 1 |
| Gontero, P | 1 |
| Sharma, AK | 1 |
| Gupta, N | 1 |
| Kala, DK | 1 |
| Patni, T | 1 |
| Dixit, R | 1 |
| Verma, S | 1 |
| Chandran, A | 1 |
| Al-Shaer, MH | 1 |
| Alghamdi, WA | 1 |
| Alsultan, A | 1 |
| An, G | 1 |
| Ahmed, S | 1 |
| Alkabab, Y | 1 |
| Banu, S | 1 |
| Barbakadze, K | 1 |
| Houpt, E | 1 |
| Kipiani, M | 1 |
| Mikiashvili, L | 1 |
| Cegielski, JP | 1 |
| Heysell, SK | 2 |
| Peloquin, CA | 7 |
| Chernyaeva, E | 1 |
| Fedorova, E | 1 |
| Zhemkova, G | 1 |
| Korneev, Y | 1 |
| Kozlov, A | 1 |
| Ahmed, I | 1 |
| Jabeen, K | 1 |
| Inayat, R | 1 |
| Hasan, R | 2 |
| Van der Walt, M | 1 |
| Lancaster, J | 1 |
| Odendaal, R | 1 |
| Davis, JG | 1 |
| Shean, K | 1 |
| Farley, J | 1 |
| Ziganshina, LE | 3 |
| Titarenko, AF | 1 |
| Davies, GR | 1 |
| Mpagama, SG | 1 |
| Ndusilo, N | 1 |
| Stroup, S | 1 |
| Kumburu, H | 1 |
| Gratz, J | 1 |
| Houpt, ER | 1 |
| Kibiki, GS | 1 |
| Maimakov, T | 1 |
| Sadykova, L | 1 |
| Kalmataeva, Z | 1 |
| Kurakpaev, K | 1 |
| Šmigelskas, K | 1 |
| Trollip, AP | 1 |
| Moore, D | 1 |
| Coronel, J | 1 |
| Caviedes, L | 1 |
| Klages, S | 1 |
| Victor, T | 1 |
| Romancenco, E | 1 |
| Crudu, V | 1 |
| Ajbani, K | 1 |
| Vineet, VP | 1 |
| Rodrigues, C | 1 |
| Jackson, RL | 1 |
| Eisenach, K | 1 |
| Garfein, RS | 1 |
| Rodwell, TC | 1 |
| Desmond, E | 1 |
| Groessl, EJ | 1 |
| Ganiats, TG | 1 |
| Catanzaro, A | 1 |
| Apsindzelashvili, R | 1 |
| Şimşek, H | 1 |
| Tarhan, G | 1 |
| Cesur, S | 1 |
| Wang, JY | 1 |
| Lee, CH | 1 |
| Yu, MC | 2 |
| Lee, MC | 1 |
| Lee, LN | 1 |
| Wang, JT | 1 |
| Javed, I | 1 |
| Mahmood, Z | 1 |
| Shahid, M | 1 |
| Khaliq, T | 1 |
| Zheng, X | 1 |
| Zheng, R | 1 |
| Hu, Y | 1 |
| Forsman, LD | 1 |
| Mansjö, M | 1 |
| Xu, B | 1 |
| Disratthakit, A | 1 |
| Prammananan, T | 1 |
| Tribuddharat, C | 1 |
| Thaipisuttikul, I | 1 |
| Doi, N | 1 |
| Leechawengwongs, M | 1 |
| Chaiprasert, A | 1 |
| Yu, X | 1 |
| Wang, G | 1 |
| Chen, S | 1 |
| Wei, G | 1 |
| Shang, Y | 1 |
| Dong, L | 1 |
| Schön, T | 1 |
| Moradigaravand, D | 1 |
| Parkhill, J | 1 |
| Peacock, SJ | 1 |
| Köser, CU | 1 |
| Huang, H | 1 |
| Javaid, A | 1 |
| Zafar, A | 1 |
| Chaudry, MA | 1 |
| Qayyum, S | 1 |
| Qadeer, E | 1 |
| Shaheen, Z | 1 |
| Agha, N | 1 |
| Rizvi, N | 1 |
| Afridi, MZ | 1 |
| Chima, MK | 1 |
| Khan, AR | 1 |
| Ghafoor, A | 1 |
| Khan, S | 1 |
| Awan, SR | 1 |
| Akhtar, S | 1 |
| Choudry, K | 1 |
| Iqbal, ZH | 1 |
| Ansarie, M | 1 |
| Ahmad, N | 1 |
| Sokolova, GB | 2 |
| Kirtaeva, OV | 1 |
| Lazareva, IaV | 2 |
| Tsybanev, AA | 1 |
| Kunichan, AD | 1 |
| Tong, XD | 1 |
| Li, MZ | 1 |
| Zhou, BP | 1 |
| Chen, XC | 1 |
| Peng, YZ | 1 |
| Yue, XH | 1 |
| Gou, JZ | 1 |
| Tang, ZJ | 1 |
| Tabarsi, P | 1 |
| Chitsaz, E | 1 |
| Baghaei, P | 1 |
| Shamaei, M | 1 |
| Farnia, P | 1 |
| Marjani, M | 1 |
| Kazempour, M | 1 |
| Amiri, M | 1 |
| Mansouri, D | 1 |
| Masjedi, MR | 1 |
| Velayati, AA | 1 |
| Caminero, JA | 1 |
| Yin, X | 1 |
| Yu, Z | 1 |
| Sawahata, M | 1 |
| Hagiwara, E | 2 |
| Ogura, T | 2 |
| Komatsu, S | 2 |
| Sekine, A | 2 |
| Tsuchiya, N | 1 |
| Takahashi, H | 2 |
| Chang, KC | 1 |
| Leung, CC | 2 |
| Tam, CM | 3 |
| Yew, WW | 11 |
| Kunogi, M | 1 |
| Kawabe, Y | 1 |
| Suzuki, J | 1 |
| Shimada, M | 1 |
| Kaneko, Y | 1 |
| Matsui, Y | 1 |
| Kawashima, M | 1 |
| Ohshima, N | 1 |
| Ariga, H | 1 |
| Masuda, K | 1 |
| Matsui, H | 1 |
| Tamura, A | 1 |
| Nagai, H | 1 |
| Akagawa, S | 1 |
| Nagayama, N | 1 |
| Toyota, E | 1 |
| Machida, K | 1 |
| Nakajima, Y | 1 |
| Jain, P | 1 |
| Hartman, TE | 1 |
| Eisenberg, N | 1 |
| O'Donnell, MR | 1 |
| Kriakov, J | 1 |
| Govender, K | 1 |
| Makume, M | 1 |
| Thaler, DS | 1 |
| Hatfull, GF | 1 |
| Sturm, AW | 1 |
| Larsen, MH | 1 |
| Moodley, P | 1 |
| Jacobs, WR | 1 |
| Kobashi, Y | 1 |
| Mouri, K | 1 |
| Obase, Y | 1 |
| Kato, S | 1 |
| Oka, M | 1 |
| Nosova, EY | 1 |
| Bukatina, AA | 1 |
| Isaeva, YD | 1 |
| Makarova, MV | 1 |
| Galkina, KY | 1 |
| Moroz, AM | 1 |
| Porwal, C | 1 |
| Kaushik, A | 1 |
| Makkar, N | 1 |
| Banavaliker, JN | 1 |
| Hanif, M | 1 |
| Singla, R | 1 |
| Bhatnagar, AK | 1 |
| Behera, D | 1 |
| Pande, JN | 1 |
| Singh, UB | 1 |
| Richeldi, L | 1 |
| Covi, M | 1 |
| Ferrara, G | 1 |
| Franco, F | 1 |
| Vailati, P | 1 |
| Meschiari, E | 1 |
| Fabbri, LM | 1 |
| Velluti, G | 1 |
| Vishnevskiĭ, BI | 1 |
| Narvskaia, OV | 1 |
| Mokrousov, IV | 1 |
| Istomin, EA | 1 |
| Otten, TF | 1 |
| Maroto Arce, N | 1 |
| Ponce, M | 1 |
| Chau, CH | 6 |
| Lee, J | 6 |
| Chen, QL | 1 |
| Chen, L | 1 |
| Yin, JJ | 1 |
| Mishin, VIu | 1 |
| Vasil'eva, IA | 1 |
| Huang, XR | 1 |
| Gao, WW | 1 |
| Zhang, XX | 1 |
| Wang, SM | 1 |
| Pan, YX | 1 |
| Ma, Y | 1 |
| Park, SK | 1 |
| Lee, WC | 1 |
| Lee, DH | 1 |
| Mitnick, CD | 1 |
| Han, L | 1 |
| Seung, KJ | 1 |
| Zheng, XM | 1 |
| Li, SM | 1 |
| Xing, BC | 1 |
| Kam, KM | 2 |
| Yip, CW | 1 |
| Sanders, CA | 1 |
| Nieda, RR | 1 |
| Desmond, EP | 1 |
| Li, JH | 1 |
| Wang, YZ | 1 |
| Zhang, HJ | 1 |
| Ramarokoto, H | 1 |
| Andrianasolo, D | 1 |
| Rasolonavalona, T | 1 |
| Ramaroson, F | 1 |
| Razafitsiarovana, I | 1 |
| Vincent, V | 1 |
| Ratsimba, L | 1 |
| Rasolofo Razanamparany, V | 1 |
| Dam, T | 1 |
| Isa, M | 1 |
| Bose, M | 1 |
| Toungoussova, OS | 1 |
| Mariandyshev, AO | 1 |
| Bjune, G | 1 |
| Caugant, DA | 1 |
| Sandven, P | 1 |
| Martin, A | 1 |
| Palomino, JC | 1 |
| Portaels, F | 2 |
| Vizel, AA | 1 |
| Squire, SB | 2 |
| Gibbons, FK | 1 |
| Branda, JA | 1 |
| Shepard, JA | 1 |
| Kim, HJ | 1 |
| Kang, CH | 1 |
| Kim, YT | 1 |
| Sung, SW | 1 |
| Kim, JH | 1 |
| Lee, SM | 1 |
| Yoo, CG | 1 |
| Lee, CT | 1 |
| Kim, YW | 1 |
| Han, SK | 1 |
| Shim, YS | 1 |
| Yim, JJ | 1 |
| Johnson, JL | 2 |
| Hadad, DJ | 2 |
| Boom, WH | 2 |
| Daley, CL | 1 |
| Eisenach, KD | 1 |
| Jankus, DD | 1 |
| Debanne, SM | 1 |
| Charlebois, ED | 1 |
| Maciel, E | 1 |
| Palaci, M | 2 |
| Dietze, R | 2 |
| Chiang, CY | 1 |
| Enarson, DA | 1 |
| Bai, KJ | 1 |
| Huang, RM | 1 |
| Hsu, CJ | 1 |
| Suo, J | 1 |
| Lin, TP | 1 |
| Szklo, A | 1 |
| Mello, FC | 1 |
| Guerra, RL | 1 |
| Dorman, SE | 1 |
| Muzy-de-Souza, GR | 1 |
| Conde, MB | 1 |
| Molino, LP | 1 |
| Grupper, M | 1 |
| Potasman, I | 1 |
| Sato, T | 1 |
| Baba, T | 1 |
| Shinohara, T | 1 |
| Endo, T | 1 |
| Sogo, Y | 1 |
| Nishihira, R | 1 |
| Matsumoto, Y | 1 |
| Tsukamura, M | 5 |
| Yanase, M | 2 |
| Bagnato, GF | 1 |
| Di Cesare, E | 1 |
| Gulli, S | 1 |
| Cucinotta, D | 1 |
| Miya, T | 1 |
| Hamakubo, S | 1 |
| Goya, T | 1 |
| Hanaoka, T | 1 |
| Hosaka, K | 1 |
| Mühlberger, F | 1 |
| Nturanye, F | 1 |
| Nasbimana, J | 1 |
| Berning, SE | 2 |
| Madsen, L | 1 |
| Iseman, MD | 1 |
| Klemens, SP | 1 |
| Sharpe, CA | 1 |
| Rogge, MC | 1 |
| Cynamon, MH | 1 |
| Cambau, E | 1 |
| Sougakoff, W | 1 |
| Besson, M | 1 |
| Truffot-Pernot, C | 1 |
| Grosset, J | 1 |
| Jarlier, V | 1 |
| Wong, PC | 6 |
| Wong, CF | 2 |
| Cheung, SW | 1 |
| Chan, CY | 1 |
| Cheng, AF | 1 |
| Sahoo, RC | 1 |
| Shah, A | 1 |
| Bhagat, R | 1 |
| Panchal, N | 1 |
| Faravelli, B | 1 |
| Wen, KH | 1 |
| Tanaka, E | 1 |
| Zalaudek, G | 1 |
| Iwanaga, T | 1 |
| Yokota, K | 1 |
| Kishikawa, R | 1 |
| Ikeda, T | 1 |
| Tsurutani, H | 1 |
| Hirose, T | 1 |
| Nishima, S | 1 |
| Ridzon, R | 1 |
| Meador, J | 1 |
| Maxwell, R | 1 |
| Higgins, K | 1 |
| Weismuller, P | 1 |
| Onorato, IM | 1 |
| Michałowska-Mitczuk, D | 1 |
| Kuś, J | 1 |
| el-Sadr, WM | 2 |
| Perlman, DC | 2 |
| Matts, JP | 2 |
| Nelson, ET | 2 |
| Cohn, DL | 1 |
| Salomon, N | 1 |
| Olibrice, M | 1 |
| Medard, F | 1 |
| Chirgwin, KD | 2 |
| Mildvan, D | 1 |
| Jones, BE | 1 |
| Telzak, EE | 2 |
| Klein, O | 1 |
| Heifets, L | 1 |
| Hafner, R | 1 |
| Ye, Z | 1 |
| Pei, X | 1 |
| Yang, Y | 1 |
| Sepkowitz, KA | 1 |
| Benson, CA | 1 |
| Zhang, Y | 1 |
| Qian, H | 1 |
| Chen, M | 1 |
| Maranetra, KN | 1 |
| Mangunnegoro, H | 1 |
| Hudoyo, A | 1 |
| Martín Marco, A | 1 |
| Falquera Sacrest, M | 1 |
| Rubio Cabàllero, M | 1 |
| Chan, CK | 1 |
| Sirgel, FA | 1 |
| Donald, PR | 1 |
| Odhiambo, J | 1 |
| Githui, W | 1 |
| Umapathy, KC | 1 |
| Paramasivan, CN | 1 |
| Lam, CW | 1 |
| Sole, KM | 1 |
| Mitchison, DA | 1 |
| KiaNoury, D | 1 |
| Timpone, J | 1 |
| Yeager, H | 1 |
| Chierakul, N | 1 |
| Klomsawat, D | 1 |
| Chulavatnatol, S | 1 |
| Chindavijak, B | 1 |
| Grimaldo, ER | 1 |
| Tupasi, TE | 1 |
| Rivera, AB | 1 |
| Quelapio, MI | 1 |
| Cardaño, RC | 1 |
| Derilo, JO | 1 |
| Belen, VA | 1 |
| Tahaoğlu, K | 1 |
| Törün, T | 1 |
| Sevim, T | 1 |
| Ataç, G | 1 |
| Kir, A | 1 |
| Karasulu, L | 1 |
| Ozmen, I | 1 |
| Kapakli, N | 1 |
| Saigal, S | 1 |
| Agarwal, SR | 1 |
| Nandeesh, HP | 1 |
| Sarin, SK | 1 |
| Reid, J | 1 |
| Marciniuk, D | 1 |
| Hoeppner, V | 1 |
| Takemura, Y | 1 |
| Iwasaki, Y | 1 |
| Minagawa, T | 1 |
| Nakanishi, M | 1 |
| Nagata, K | 1 |
| Natsuhara, A | 1 |
| Harada, H | 1 |
| Nakagawa, M | 1 |
| Stambaugh, JJ | 1 |
| Bulpitt, AE | 1 |
| Hollender, ES | 1 |
| Narita, M | 1 |
| Ashkin, D | 1 |
| Zwoliński, J | 1 |
| Gałazka, J | 1 |
| Kwan, SY | 3 |
| Kawahara, S | 1 |
| Eirei, J | 1 |
| Kohno, S | 1 |
| Koga, H | 1 |
| Kaku, M | 1 |
| Maesaki, S | 1 |
| Hara, K | 1 |
| Koriakin, VA | 1 |
| Zeliger, LR | 1 |
| Galenko, NN | 1 |
| Nakae, I | 1 |
| Nakatani, K | 1 |
| Inoue, S | 1 |
| Takahasi, K | 1 |
| Ikeda, N | 2 |
| Matsumoto, T | 2 |
| Ozawa, S | 1 |
| Sakatani, M | 2 |
| Kita, N | 4 |
| Tanaka, S | 1 |
| Ma, WK | 1 |
| Khin, MA | 1 |
| Chau, PY | 1 |
| Krasucka-Kluźniak, A | 1 |
| Krakówka, P | 1 |
| Chen, CH | 1 |
| Shih, JF | 1 |
| Lindholm-Levy, PJ | 1 |
| Heifets, LB | 1 |
| Kanetsuna, F | 1 |
| Ueda, E | 1 |
| Yamazaki, M | 1 |
| Kanai, K | 1 |
| Sirai, F | 1 |
| Iwagaki, K | 1 |
| Takenaka, K | 1 |
| Arai, R | 1 |
| Kawahara, M | 1 |
| Furuse, K | 1 |
| Yoshii, S | 2 |
| Yasuda, Y | 2 |
| Saito, H | 1 |
| Schmücker, P | 1 |
| Cassier, C | 1 |
| Koch, G | 1 |
| Tsunekawa, H | 1 |
| Miyachi, T | 1 |
| Nakamura, E | 2 |
| Amano, H | 2 |
| Shimoide, H | 1 |
| Yoshimoto, K | 1 |
| Wada, T | 1 |
| Mitani, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Leveraging mHealth to Enable and Adapt Community Health Worker Strategies to Improve TB/HIV Patient Outcomes in South Africa (LEAP-TB-SA) Trial[NCT04298905] | 200 participants (Anticipated) | Interventional | 2022-03-10 | Recruiting | |||
| A Randomized Clinical Trial of Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa[NCT04618198] | Phase 3 | 436 participants (Anticipated) | Interventional | 2021-12-10 | Recruiting | ||
| Randomized, Open Label, Multiple Dose Phase I Study of the Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, and Moxifloxacin in HIV-non-infected Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis[NCT00396084] | Phase 1/Phase 2 | 70 participants (Actual) | Interventional | 2004-02-10 | Completed | ||
| STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB[NCT02409290] | Phase 3 | 588 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811] | 625 participants (Anticipated) | Observational | 2020-01-30 | Recruiting | |||
| The Treatment of Pulmonary Mycobacterium Tuberculosis in HIV Infection[NCT00001033] | Phase 3 | 650 participants | Interventional | Completed | |||
| Randomized Clinical Trial to Assess the Efficacy of Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis[NCT00376012] | Phase 3 | 300 participants (Actual) | Interventional | 2001-02-28 | Active, not recruiting | ||
| A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in[NCT00000796] | 525 participants | Interventional | Completed | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Area Under the Curve (AUC) During First 12 or 24 Hours /Minimum Inhibitory Concentration. AUC reflects total drug (bound and unbound). MIC values were determined using protein-containing media. (NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | ug/ml (Median) |
|---|---|
| Gatifloxacin 400 mg/Day | 85.6 |
| Levofloxacin 1000 mg/Day | 129.1 |
| Moxifloxacin 400 mg/Day | 110.5 |
| Isoniazid (INH) 300 mg/Day | 215.2 |
Early bactericidal activity (EBA 0-2) was calculated as the rate of fall in sputum colony forming units (cfu) (expressed in log10 units) during the first 2 days of monotherapy. (NCT00396084)
Timeframe: Day 0 to Day 2 Monotherapy
| Intervention | log10 cfu/ml/day (Mean) |
|---|---|
| Gatifloxacin 400 mg/Day | 0.35 |
| Levofloxacin 1000 mg/Day | 0.45 |
| Moxifloxacin 400 mg/Day | 0.33 |
| Isoniazid (INH) 300 mg/Day | 0.67 |
Early bactericidal activity (EBA 0-2) was calculated as the rate of fall in sputum cfu (expressed in log10 units) during the first 2 days of monotherapy. Mean values for the 3 treatment groups were compared. (NCT00396084)
Timeframe: Day 0 to Day 2 Monotherapy
| Intervention | log10 cfu/ml/day (Mean) |
|---|---|
| Isoniazid 300 mg/Day | 0.67 |
| Linezolid 600 mg/Once Daily | 0.18 |
| Linezolid 600 mg/Twice Daily | 0.26 |
The rate of fall in sputum cfu between day 2 and day 7 of monotherapy was estimated by the slope of the linear regression obtained by fitting the 6 sputum cfu values corresponding to Days 2 through 7. (NCT00396084)
Timeframe: Day 2 to Day 7 Monotherapy
| Intervention | log10 cfu/ml (Mean) |
|---|---|
| Isoniazid 300 mg/Day | 0.16 |
| Linezolid 600 mg/Once Daily | 0.09 |
| Linezolid 600 mg/Twice Daily | 0.04 |
The rate of fall in sputum cfu between day 2 and day 7 of monotherapy was estimated by the slope of the linear regression obtained by fitting the 6 sputum cfu values corresponding to Days 2 through 7. (NCT00396084)
Timeframe: Day 2 to Day 7 Monotherapy
| Intervention | log10 cfu/ml/day (Mean) |
|---|---|
| Gatifloxacin 400 mg/Day | 0.17 |
| Levofloxacin 1000 mg/Day | 0.18 |
| Moxifloxacin 400 mg/Day | 0.17 |
| Isoniazid (INH) 300 mg/Day | 0.08 |
Maximum plasma concentration, given sampling scheme (NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | ug/ml (Median) |
|---|---|
| Gatifloxacin 400 mg/Day | 4.8 |
| Levofloxacin 1000 mg/Day | 15.6 |
| Moxifloxacin 400 mg/Day | 6.1 |
| Isoniazid (INH) 300 mg/Day | 3.6 |
Maximum Plasma Drug Concentration (Cmax), given sampling scheme (NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | ug/ml (Median) |
|---|---|
| Isoniazid 300 mg/Day | 3.3 |
| Linezolid 600 mg/Once Daily | 15.0 |
| Linezolid 600 mg/Twice Daily | 19.4 |
(NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | ug/ml (Median) |
|---|---|
| Gatifloxacin 400 mg/Day | 9.5 |
| Levofloxacin 1000 mg/Day | 15.6 |
| Moxifloxacin 400 mg/Day | 12.3 |
| Isoniazid (INH) 300 mg/Day | 70.6 |
(NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | ug/ml (Median) |
|---|---|
| Isoniazid 300 mg/Day | 62.7 |
| Linezolid 600 mg/Once Daily | 20.0 |
| Linezolid 600 mg/Twice Daily | 16.2 |
Cmax adjusted for free drug concentrations after 5 days of monotherapy with study drugs (NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | ug/ml (Median) |
|---|---|
| Isoniazid 300 mg/Day | 3.1 |
| Linezolid 600 mg/Once Daily | 10.3 |
| Linezolid 600 mg/Twice Daily | 13.4 |
Determined by linear extrapolation of concentration-versus-time curve to intersection with MIC. (NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | Percentage (Mean) |
|---|---|
| Isoniazid (INH) 300 mg/Day | 95.5 |
| Linezolid 600 mg/Once Daily | 62.8 |
| Linezolid 600 mg/Twice Daily | 100.0 |
Area under the curve (AUC), from time 0-12 hours for INH or 0-24 hours for gatifloxacin, levofloxacin, and moxifloxacin. (NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | ug/h/ml (Median) |
|---|---|
| Gatifloxacin 400 mg/Day | 42.8 |
| Levofloxacin 1000 mg/Day | 129.1 |
| Moxifloxacin 400 mg/Day | 55.3 |
| Isoniazid (INH) 300 mg/Day | 11.9 |
Area Under the Curve 0-12 (AUC 0-12) Adjusted for Free Drug Concentrations/Minimum Inhibitory Concentration (MIC) and AUC 0-24/MIC (NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | ug/h/ml (Median) | |
|---|---|---|
| AUC 0-12/MIC | AUC 0-24/MIC | |
| Isoniazid 300 mg/Day | 306.7 | 344.6 |
| Linezolid 600 mg/Once Daily | 107.8 | 116.2 |
| Linezolid 600 mg/Twice Daily | 121.6 | 243.2 |
Median pharmacodynamic parameters (range) adjusted for free drug concentrations. AUC 0-12 and AUC 0-24 = area under the curve during the first 12 and 24 hours after dosing, respectively (NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | ug/h/ml (Median) | |
|---|---|---|
| AUC 0-12 | AUC 0-24 | |
| Isoniazid 300 mg/Day | 15.3 | 17.2 |
| Linezolid 600 mg/Once Daily | 60.1 | 66.8 |
| Linezolid 600 mg/Twice Daily | 80.3 | 160.7 |
Median pharmacokinetic parameters (range). AUC 0-12 and AUC 0-24 = area under the curve during the first 12 and 24 hours after dosing, respectively (NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | ug/h/ml (Median) | |
|---|---|---|
| AUC 0-12 (ug/h/ml) | AUC 0-24 (ug/h/ml) | |
| Isoniazid 300 mg/Day | 17.0 | 19.2 |
| Linezolid 600 mg/Once Daily | 87.0 | 96.9 |
| Linezolid 600 mg/Twice Daily | 116.4 | 232.9 |
The adjusted area under the curve (aAUC) for sputum colony forming unit (cfu) for each day on treatment was calculated for patients in the INH arm and those in the Linezolid once daily and Linezolid twice daily arms. The aAUC represents the percentage of the expected AUC given no change in log cfu in response to study drug administration. (NCT00396084)
Timeframe: Study drug administration duration - 7 days monotherapy
| Intervention | Percentage (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | |
| Isoniazid 300 mg/Day | 0.94 | 0.89 | 0.89 | 0.85 | 0.83 | 0.81 | 0.83 |
| Linezolid 600 mg/Once Daily | 0.98 | 0.97 | 0.96 | 0.96 | 0.95 | 0.95 | 0.95 |
| Linezolid 600 mg/Twice Daily | 0.98 | 0.96 | 0.95 | 0.94 | 0.94 | 0.93 | 0.93 |
The adjusted area under the curve (aAUC) for sputum colony forming units (cfu) for each day on treatment was calculated. The aAUC represents the percentage of the expected AUC given no change in log cfu in response to study drug administration. (NCT00396084)
Timeframe: Study drug administration duration - 7 days monotherapy
| Intervention | Percentage (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | |
| Gatifloxacin 400 mg/Day | 0.98 | 0.96 | 0.92 | 0.89 | 0.87 | 0.85 | 0.82 |
| Isoniazid (INH) 300 mg/Day | 0.95 | 0.90 | 0.87 | 0.84 | 0.81 | 0.80 | 0.80 |
| Levofloxacin 1000 mg/Day | 0.98 | 0.95 | 0.91 | 0.88 | 0.85 | 0.83 | 0.81 |
| Moxifloxacin 400 mg/Day | 0.96 | 0.94 | 0.91 | 0.89 | 0.87 | 0.85 | 0.83 |
(NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | hours (Median) | |
|---|---|---|
| Tmax in h (apparent time of max plasma conc.) | Half-life | |
| Isoniazid 300 mg/Day | 1.0 | 3.6 |
| Linezolid 600 mg/Once Daily | 1.5 | 3.20 |
| Linezolid 600 mg/Twice Daily | 1.0 | 4.56 |
(NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | hours (Median) | |
|---|---|---|
| Tmax | Half-life | |
| Gatifloxacin 400 mg/Day | 1.5 | 6.0 |
| Isoniazid (INH) 300 mg/Day | 1 | 2.5 |
| Levofloxacin 1000 mg/Day | 1.0 | 7.6 |
| Moxifloxacin 400 mg/Day | 1.0 | 8.1 |
probable or definite failure or recurrence (FoR) (NCT02409290)
Timeframe: final efficacy week (between 96 and 132 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 17 |
| Regimen C (Oral Regimen) | 4 |
| Regimen D (6-month Regimen) | 0 |
The proportion of patients with failure or recurrence (FoR) (NCT02409290)
Timeframe: 132 weeks, control regimen (arm B) using concurrent controls only
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen B (Control Regimen) | 14 |
| Regimen D (6-month Regimen) | 2 |
The proportion of patients with a favourable outcome at their last efficacy visit (NCT02409290)
Timeframe: Last efficacy visit, between 96 and 132 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 17 |
| Regimen B (Control Regimen) | 126 |
| Regimen C (Oral Regimen) | 152 |
| Regimen D (6-month Regimen) | 115 |
The proportion of patients with acquired drug resistance (any drug) (NCT02409290)
Timeframe: 132 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 5 |
| Regimen C (Oral Regimen) | 5 |
| Regimen D (6-month Regimen) | 3 |
The primary efficacy outcome of the STREAM Stage 2 comparison is status at Week 76 i.e. the proportion of patients with a favourable outcome at Week 76 (NCT02409290)
Timeframe: 76 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 133 |
| Regimen C (Oral Regimen) | 162 |
| Regimen D (6-month Regimen) | 122 |
6 reviews available for ofloxacin and Tuberculosis, Pulmonary
| Article | Year |
|---|---|
Fluoroquinolones for treating tuberculosis (presumed drug-sensitive).
Topics: Antitubercular Agents; Ciprofloxacin; Drug Substitution; Fluoroquinolones; Humans; Levofloxacin; Ofl | 2013 |
[Pulmonary mycobacteriosis caused by Mycobacterium peregrinum in a young, healthy man].
Topics: Clarithromycin; Drug Therapy, Combination; Ethambutol; Humans; Levofloxacin; Male; Mycobacterium Inf | 2010 |
[Tuberculosis and the digestive tract].
Topics: Adenosine Deaminase; Antitubercular Agents; Ascitic Fluid; Biomarkers; CA-125 Antigen; Chemical and | 2003 |
Fluoroquinolones for treating tuberculosis.
Topics: Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Randomized | 2005 |
Fluoroquinolones for treating tuberculosis.
Topics: Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Randomized | 2008 |
Minimal inhibitory concentrations of rifabutin, ciprofloxacin, and ofloxacin against Mycobacterium tuberculosis isolated before treatment of patients in Taiwan.
Topics: Antitubercular Agents; Ciprofloxacin; Culture Media; Dose-Response Relationship, Drug; Drug Resistan | 1989 |
18 trials available for ofloxacin and Tuberculosis, Pulmonary
| Article | Year |
|---|---|
[Floracide, a Russian 3rd generation fluoroquinolone in complex therapy of tuberculosis].
Topics: Adult; Antitubercular Agents; Arthralgia; Diarrhea; Drug Resistance, Multiple, Bacterial; Drug Thera | 2008 |
[Levofloxacin (Tavanic) in complex therapy of tuberculosis].
Topics: Adult; Animals; Antitubercular Agents; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bact | 2009 |
[Efficacy of ofloxacin (zanocin) in the treatment of multidrug resistant pulmonary tuberculosis].
Topics: Administration, Oral; Adult; Anti-Infective Agents; Antitubercular Agents; Diarrhea; Drug Resistance | 2003 |
[Short-term effect of treatment protocol utilizing levofloxacin, pasiniazide and M. Vaccae on multi- drug resistant pulmonary tuberculosis].
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aminosalicylic Acid; Aminosalicylic Acids; Clinical | 2004 |
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifl | 2006 |
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifl | 2006 |
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifl | 2006 |
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifl | 2006 |
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifl | 2006 |
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifl | 2006 |
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifl | 2006 |
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifl | 2006 |
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifl | 2006 |
Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Brazil; Female; Fluoroqui | 2008 |
[Pilot studies on the treatment of Mycobacterium avium complex lung disease--new macrolides and new quinolones. (2) Multi-drug chemotherapy for initial cases on trial].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Antitubercular Agents; Cl | 1996 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D | 1998 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D | 1998 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D | 1998 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D | 1998 |
[Analysis of causes of drug resistance and therapeutic effects on 27 multi-drug resistant pulmonary tuberculosis patients].
Topics: Adult; Aminosalicylic Acid; Anti-Infective Agents; Antitubercular Agents; Drug Resistance, Multiple; | 1997 |
[Bronchofiberscope and catheter intervention in treatment of multi-drug resistant pulmonary tuberculosis].
Topics: Adult; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bronchoscopy; Catheterization, Periph | 1997 |
Efficacy of low-dose ofloxacin in the treatment of multidrug-resistant tuberculosis in Indonesia.
Topics: Adolescent; Adult; Anti-Infective Agents; Female; Humans; Male; Middle Aged; Ofloxacin; Treatment Ou | 1999 |
A multicentre study of the early bactericidal activity of anti-tuberculosis drugs.
Topics: Adult; Anti-Infective Agents; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Micr | 2000 |
Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report.
Topics: Adolescent; Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Drug Therap | 2001 |
A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Hong Kong Chest Service/British Medical Research Council.
Topics: Adult; Aged; Antitubercular Agents; Chronic Disease; Dose-Response Relationship, Drug; Drug Resistan | 1992 |
[Evaluation of new antitubercular agents--new quinolone agents].
Topics: Antitubercular Agents; Drug Resistance, Microbial; Humans; Mycobacterium tuberculosis; Ofloxacin; Qu | 1992 |
Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Combinations; Drug Resistance, Microbial; Ethambuto | 1992 |
[Therapeutic effect of ofloxacin on intractable pulmonary tuberculosis and ofloxacin resistance of tubercle bacilli isolated from the patients. Chest DIsease Cooperative Study Unit of National Sanatoriums in Kinki District].
Topics: Adult; Aged; Aged, 80 and over; Drug Resistance, Microbial; Female; Humans; Male; Middle Aged; Mycob | 1991 |
[2 cases of drug-resistant pulmonary tuberculosis treated with ofloxacin].
Topics: Adult; Antitubercular Agents; Chronic Disease; Clinical Trials as Topic; Drug Resistance, Microbial; | 1989 |
92 other studies available for ofloxacin and Tuberculosis, Pulmonary
| Article | Year |
|---|---|
Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
Topics: Acute Disease; Administration, Oral; Animals; Antitubercular Agents; Bacterial Proteins; Biological | 2014 |
Impact of
Topics: Acetyltransferases; Antitubercular Agents; Bacterial Proteins; Base Sequence; Capreomycin; DNA Gyras | 2017 |
Miliary pulmonary infection after BCG intravesical instillation: a rare, misdiagnosed and mistreated complication.
Topics: Aged; Antitubercular Agents; BCG Vaccine; Bronchoalveolar Lavage Fluid; Carcinoma, Transitional Cell | 2017 |
A study on pattern of resistance to second line anti tubercular drugs among multi drug resistant tuberculosis patients.
Topics: Aminoglycosides; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resis | 2018 |
Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Ciprofloxacin; Dose-Response Rela | 2019 |
Characterization of multiple and extensively drug resistant Mycobacterium tuberculosis isolates with different ofloxacin-resistance levels.
Topics: Amino Acid Substitution; Antitubercular Agents; DNA Gyrase; Dose-Response Relationship, Drug; Drug R | 2013 |
Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate.
Topics: Acetamides; Amoxicillin-Potassium Clavulanate Combination; Antitubercular Agents; Extensively Drug-R | 2013 |
Serious treatment related adverse drug reactions amongst anti-retroviral naïve MDR-TB patients.
Topics: Adult; Antitubercular Agents; Coinfection; Cycloserine; Drug Resistance, Multiple, Bacterial; Female | 2013 |
Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
Topics: Adolescent; Adult; Amikacin; Antitubercular Agents; Cycloserine; Ethionamide; Female; Fluoroquinolon | 2014 |
Treatment of tuberculosis in South Kazakhstan: clinical and economical aspects.
Topics: Adult; Anti-Bacterial Agents; Antitubercular Agents; Capreomycin; Cycloserine; Drug Costs; Female; H | 2013 |
Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones | 2014 |
Performance of the MTBDRsl assay in Georgia.
Topics: Antitubercular Agents; Capreomycin; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant | 2014 |
[Evaluation of second-line antituberculosis drug susceptibilities of multidrug-resistant Mycobacterium tuberculosis complex isolates by E-test method].
Topics: Acetamides; Antitubercular Agents; Culture Media; Drug Resistance, Multiple, Bacterial; Ethionamide; | 2015 |
Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; | 2015 |
Identification of ofloxacin-resistant Mycobacterium tuberculosis by PCR-RFLP and Sequencing.
Topics: Antitubercular Agents; Codon; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Mycob | 2016 |
Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.
Topics: Adolescent; Adult; Aged; Amikacin; Antitubercular Agents; China; Drug Therapy, Combination; Female; | 2016 |
Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
Topics: Aminopyridines; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Extens | 2016 |
Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin.
Topics: Antitubercular Agents; China; DNA Gyrase; Drug Dosage Calculations; Drug Resistance, Bacterial; Fluo | 2016 |
Pattern of first- and second-line drug resistance among pulmonary tuberculosis retreatment cases in Pakistan.
Topics: Adolescent; Adult; Antitubercular Agents; Cross-Sectional Studies; Extensively Drug-Resistant Tuberc | 2017 |
[The effect of CD4+ CD25+ regulatory T cell inactivation combined with levofloxacin on murine tuberculosis].
Topics: Animals; Anti-Bacterial Agents; Female; Levofloxacin; Mice; Mice, Inbred C57BL; Ofloxacin; T-Lymphoc | 2009 |
Impact of extensively drug-resistant tuberculosis on treatment outcome of multidrug-resistant tuberculosis patients with standardized regimen: report from Iran.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Clinical Protocols; Cycloserine; Drug Resistance, Multiple, | 2010 |
Mutation characterization of gyrA and gyrB genes in levofloxacin-resistant Mycobacterium tuberculosis clinical isolates from Guangdong Province in China.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; China; DNA Gyrase; DNA, Bacterial; Drug Resistance, | 2010 |
Streptomycin susceptibility and MDR-TB: can we refine the definition of XDR-TB?
Topics: Antitubercular Agents; Extensively Drug-Resistant Tuberculosis; Humans; Microbial Sensitivity Tests; | 2011 |
[Evaluation of tuberculosis treatment including levofloxacin (LVFX) in cases who could not continue standard regimen].
Topics: Aged; Anti-Bacterial Agents; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, B | 2011 |
φ(2)GFP10, a high-intensity fluorophage, enables detection and rapid drug susceptibility testing of Mycobacterium tuberculosis directly from sputum samples.
Topics: Antitubercular Agents; Bacteriophages; Genes, Reporter; Genetic Vectors; Green Fluorescent Proteins; | 2012 |
Pulmonary Mycobacterium kyorinense disease showed clinical improvement following combined therapy with clarithromycin and levofloxacin.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Humans; Levofloxacin; Male; Microb | 2012 |
Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.
Topics: Antitubercular Agents; Aza Compounds; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gati | 2013 |
Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi region.
Topics: Adult; Amikacin; Antitubercular Agents; Capreomycin; Ethionamide; Extensively Drug-Resistant Tubercu | 2013 |
Clinical use of Levofloxacin in the long-term treatment of drug resistant tuberculosis.
Topics: Adult; Aged; Anti-Infective Agents; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; | 2002 |
[Sensitivity to levofloxacin of Mycobacterium tuberculosis strains with various phenotype isolated from patients with newly diagnosed and chronic tuberculosis].
Topics: Anti-Infective Agents; Chronic Disease; Drug Resistance, Bacterial; Genotype; Humans; Levofloxacin; | 2002 |
Superficial fungal infection of the skin during treatment of tuberculosis.
Topics: Anti-Infective Agents; Dermatomycoses; Humans; Male; Middle Aged; Ofloxacin; Tuberculosis, Pulmonary | 2002 |
[A study on the clinical efficacy of a combination regimen with levofloxacin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis].
Topics: Adolescent; Adult; Antitubercular Agents; Capreomycin; Drug Therapy, Combination; Female; Humans; Le | 2003 |
[A preliminary study on the definition of resistant breakpoints of ofloxacin and levofloxacin for Mycobacterium tuberculosis].
Topics: Adolescent; Adult; Aged; Drug Resistance, Bacterial; Female; Humans; Levofloxacin; Male; Microbial S | 2004 |
Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acid; Antitubercular Agents; Cohort Studi | 2004 |
Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.
Topics: Amikacin; Anti-Bacterial Agents; Antitubercular Agents; Communicable Disease Control; Cycloserine; D | 2004 |
Validation of the use of Middlebrook 7H10 agar, BACTEC MGIT 960, and BACTEC 460 12B media for testing the susceptibility of Mycobacterium tuberculosis to levofloxacin.
Topics: Agar; Anti-Bacterial Agents; Bacteriological Techniques; Culture Media; Drug Resistance, Bacterial; | 2004 |
[Clinical observation on treatment of retreated positive tubercle bacillus pneumoconio-tuberculosis with levofloxacin].
Topics: Aged; Anti-Bacterial Agents; Humans; Levofloxacin; Middle Aged; Ofloxacin; Pneumoconiosis; Tuberculo | 2004 |
[A case of pulmonary multiresistant Mycobacterium bovis tuberculosis in Madagascar].
Topics: Amikacin; Antitubercular Agents; Capreomycin; Chronic Disease; Ciprofloxacin; Cough; DNA, Bacterial; | 2003 |
Drug-sensitivity profile of clinical Mycobacterium tuberculosis isolates--a retrospective study from a chest-disease institute in India.
Topics: Adult; Aged; Antitubercular Agents; Ciprofloxacin; Drug Resistance, Bacterial; Female; Humans; India | 2005 |
Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs.
Topics: Antitubercular Agents; Capreomycin; Drug Resistance, Multiple, Bacterial; Ethionamide; Humans; Kanam | 2005 |
Rapid detection of ofloxacin resistance in Mycobacterium tuberculosis by two low-cost colorimetric methods: resazurin and nitrate reductase assays.
Topics: Anti-Bacterial Agents; Colorimetry; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; | 2005 |
Case records of the Massachusetts General Hospital. Case 12-2006. A 37-year-old man with hemoptysis and a pulmonary infiltrate.
Topics: Adult; Anti-Infective Agents; Diagnosis, Differential; Hemoptysis; Humans; Lung; Lung Neoplasms; Mal | 2006 |
Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis.
Topics: Adult; Aged; Biomarkers; Body Mass Index; Drug Resistance, Multiple, Bacterial; Female; Humans; Lung | 2006 |
Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antitubercular Agents; Drug Resis | 2006 |
Alternative anti-tuberculosis regimen including ofloxacin for the treatment of patients with hepatic injury.
Topics: Antitubercular Agents; Brazil; Cohort Studies; Comorbidity; Confidence Intervals; Dose-Response Rela | 2007 |
Fluoroquinolones in community-acquired pneumonia when tuberculosis is around: an instructive case.
Topics: Adult; Anti-Bacterial Agents; Community-Acquired Infections; Fluoroquinolones; Humans; Levofloxacin; | 2008 |
[Case of pneumothorax associated with pulmonary Mycobacterium fortuitum infection].
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Combined Modality Therapy; Drainage; Drug Resistance, | 2008 |
[Trial of clinical administration of a new antibacterial substance DL 8280 in pulmonary tuberculosis].
Topics: Adult; Anti-Infective Agents; Female; Humans; Male; Middle Aged; Ofloxacin; Oxazines; Tuberculosis, | 1984 |
Long-term treatment of pulmonary tuberculosis with ofloxacin in a subject with liver cirrhosis.
Topics: Administration, Oral; Anti-Infective Agents; Antitubercular Agents; Ethambutol; Follow-Up Studies; H | 1995 |
Ofloxacin concentrations in serum, saliva and pleural effusion of patients with pulmonary tuberculosis and lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Carcinoma, Non-Small-Ce | 1995 |
[Ofloxacin-cycloserine-protionamide-INH combination against treatment refractory lung tuberculosis].
Topics: Adult; AIDS-Related Opportunistic Infections; Cycloserine; Dose-Response Relationship, Drug; Drug Ad | 1995 |
Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections.
Topics: Antitubercular Agents; Ciprofloxacin; Drug Administration Schedule; Female; Humans; Male; Middle Age | 1995 |
Activity of levofloxacin in a murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Culture Media; Disease Models, Animal; Dose-Response Relationship, D | 1994 |
Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin.
Topics: Adult; Antitubercular Agents; Aspartic Acid; Base Sequence; DNA Gyrase; DNA Primers; DNA Topoisomera | 1994 |
Ofloxacin and pulmonary tuberculosis.
Topics: Humans; Ofloxacin; Tuberculosis, Pulmonary | 1994 |
Correlation of serum ofloxacin concentration and serum creatinine level in patients on prolonged therapy.
Topics: Adolescent; Adult; Aged; Chromatography, High Pressure Liquid; Creatinine; Drug Administration Sched | 1993 |
Ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin--a south Indian experience.
Topics: Drug Resistance, Microbial; Humans; Mycobacterium tuberculosis; Ofloxacin; Tuberculosis, Pulmonary | 1993 |
Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after coadministration of cycloserine and ofloxacin.
Topics: Adult; Cycloserine; Depression; Drug Therapy, Combination; Humans; Male; Middle Aged; Ofloxacin; Sei | 1993 |
Resistant tuberculosis: successful treatment with amikacin, ofloxacin, clofazimine, and pas.
Topics: Adult; Amikacin; Aminosalicylic Acid; Antitubercular Agents; Clofazimine; Drug Resistance, Microbial | 1993 |
Long-term treatment of pulmonary tuberculosis with ofloxacin in a subject with liver cirrhosis.
Topics: Aged; Anti-Infective Agents; Humans; Liver Cirrhosis; Ofloxacin; Tuberculosis, Pulmonary | 1996 |
Pseudomembranous colitis in a patient treated with ofloxacin for tuberculosis.
Topics: Aged; Antitubercular Agents; Enterocolitis, Pseudomembranous; Humans; Male; Ofloxacin; Tuberculosis, | 1996 |
[Use of ofloxacin in infections which do not readily respond to treatment].
Topics: Anti-Infective Agents; Bacterial Infections; Biological Availability; Drug Resistance, Microbial; Gr | 1996 |
[The combination of amoxicillin-clavulanic acid and ofloxacin in the treatment of multidrug-resistant Mycobacterium tuberculosis].
Topics: Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Antitubercular Agents; Clavulanic | 1997 |
Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin.
Topics: Adolescent; Adult; Alanine Transaminase; Antitubercular Agents; Chemical and Drug Induced Liver Inju | 1997 |
[Treatment of patients for chronic pulmonary tuberculosis with expectoration--selection and tolerance to drugs].
Topics: Antitubercular Agents; Chronic Disease; Drug Therapy, Combination; Drug Tolerance; Humans; Incidence | 1997 |
Fluoroquinolones and tuberculosis.
Topics: Anti-Infective Agents; Ciprofloxacin; Humans; Ofloxacin; Tuberculosis, Multidrug-Resistant; Tubercul | 1998 |
Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Hea
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antitubercular Agents; Chi-Squa | 1999 |
Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Hea
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antitubercular Agents; Chi-Squa | 1999 |
Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Hea
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antitubercular Agents; Chi-Squa | 1999 |
Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Hea
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antitubercular Agents; Chi-Squa | 1999 |
Quinolones and multidrug-resistant tuberculosis.
Topics: Anti-Infective Agents; Humans; Ofloxacin; Prevalence; Thailand; Tuberculosis, Multidrug-Resistant; T | 1999 |
[Musculoskeletal clinical adverse effects of ofloxacin].
Topics: Adult; Aged; Anti-Infective Agents; Arthralgia; Arthritis; Humans; Male; Ofloxacin; Tuberculosis, Pu | 1999 |
Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens.
Topics: Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Female; Hong Kong; Humans; Levofloxac | 2000 |
Can administration of a fluoroquinolone delay diagnosis of pulmonary tuberculosis?
Topics: Adult; Bronchoalveolar Lavage Fluid; Female; Humans; Mycobacterium tuberculosis; Ofloxacin; Pneumoni | 2000 |
Intrapulmonary pharmacokinetics of ofloxacin in drug-resistant tuberculosis.
Topics: Adult; Anti-Infective Agents; Antitubercular Agents; Bronchoalveolar Lavage Fluid; Chromatography, H | 2001 |
Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines.
Topics: Anti-Infective Agents; Ciprofloxacin; Culture Media; Drug Resistance, Microbial; Drug Resistance, Mu | 2001 |
The treatment of multidrug-resistant tuberculosis in Turkey.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Isoniazid | 2001 |
Quinolones may mean shorter TB therapy.
Topics: Anti-Infective Agents; Antitubercular Agents; Clinical Trials as Topic; Drug Therapy, Combination; H | 2001 |
Pharmacokinetics of antituberculosis medications delivered via percutaneous gastrojejunostomy tube.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Female; Gastrostomy; Humans; Jejunostomy; Levoflo | 2002 |
[Mycobacterium abscessus infection complicated with diabetes mellitus].
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Cilastatin; Cilastatin, Imipen | 2002 |
Ofloxacin population pharmacokinetics in patients with tuberculosis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Infective Agents; Child; Child, Preschool; Chrom | 2002 |
[Ofloxacin in the treatment of pulmonary changes caused by Mycobacterium avium and Mycobacterium xenopii].
Topics: Humans; Male; Middle Aged; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection | 1992 |
Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Drug Monitoring; Drug Therap | 1992 |
[Tarivid in the combination therapy of patients with pulmonary tuberculosis].
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Ofloxaci | 1991 |
[Management of INH and RFP-resistant refractory tuberculosis].
Topics: Drug Resistance; Female; Humans; Isoniazid; Male; Mycobacterium tuberculosis; Ofloxacin; Rifamycins; | 1991 |
In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis.
Topics: Adult; Aged; Anti-Bacterial Agents; Drug Resistance, Microbial; Female; Humans; Isoniazid; Male; Mid | 1990 |
Ofloxacin and imipenem in the treatment of Mycobacterium fortuitum and Mycobacterium chelonae lung infections.
Topics: Adult; Female; Humans; Imipenem; Male; Middle Aged; Mycobacterium Infections, Nontuberculous; Ofloxa | 1990 |
[Rifabutine in the treatment of mycobacterial infections resistant to rifampicin. Preliminary results. Group for the Study and Treatment of Resistant Mycobacterial Infections (GETIM)].
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Drug Resistance, Microbial; Drug Therapy, Combinati | 1989 |
[Therapeutic effect of Ofloxacin on intractable pulmonary tuberculosis. Chest disease cooperative study unit of National Sanatoriums in Kinki District].
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antitubercular; Drug Evaluation; Drug Therapy, Combinat | 1988 |
[Exacerbation of pulmonary tuberculosis after diagnostic bronchoscopy and its preventive medication].
Topics: Adult; Aged; Bronchoscopy; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Middle Aged; | 1988 |
[Antituberculosis chemotherapy including ofloxacin in patients with pulmonary tuberculosis not treated previously].
Topics: Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Ofloxacin; Oxazines | 1986 |
[Case report on the effectiveness of ofloxacin (Tarivid) in large cavernous lung tuberculosis].
Topics: Drug Therapy, Combination; Female; Humans; Middle Aged; Ofloxacin; Oxazines; Tuberculosis, Pulmonary | 1987 |
[Therapeutic effect of ofloxacin on 'treatment-failure' pulmonary tuberculosis].
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Combinations; Drug Resistance, Microbial | 1987 |
[Therapeutic effect of ofloxacin (DL 8280) on pulmonary tuberculosis. (Report of a one year-administration study on sixteen treatment-failure patients)].
Topics: Anti-Bacterial Agents; Drug Evaluation; Humans; Nontuberculous Mycobacteria; Ofloxacin; Oxazines; Tu | 1985 |
[Lung infections due to Mycobacterium fortuitum and Mycobacterium chelonae. Reports of nine cases of M. fortuitum infection and four cases of M. chelonae infection].
Topics: Adolescent; Aged; Female; Humans; Male; Middle Aged; Mycobacterium Infections, Nontuberculous; Nontu | 1985 |